Although there seems to be clinical consensus on the fact that treatment‐associated hypoglycaemia is a key factor leading to insulin late initiation and reluctance to optimize the dose (titration period) administered to reach the HbA1c target, evidence available to prove the relationship between treatment‐associated hypoglycaemia and failure to reach the glycemic target is surprisingly scarce.10 The gene discussed is INS; the disease is Hypoglycemia.